Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 90,000 ordinary shares of 25 pence each.
- Purchase Price: 1,175.83 pence per share.
- Treasury Holdings: 496,269,158 shares (representing 8.98% of total voting rights).
- Shares in Issue: 5,529,026,383 (excluding Treasury shares).
Material Changes
The material change reported is the increase in the company's Treasury share holdings following the purchase of 90,000 shares on November 22, 2007. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (496,269,158) and the percentage of voting rights represented (8.98%).
- Confirm the total number of shares in issue excluding Treasury shares (5,529,026,383) for disclosure threshold calculations.
- Review the specific price paid per share (1,175.83 pence) for the November 22, 2007 transaction.